Last updated on October 2017

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

Brief description of study

To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.

Clinical Study Identifier: NCT02982954

Contact Investigators or Research Sites near you

Start Over

Hemant Patel, Site 0025

Northwest Alabama Cancer Center, Pc
Muscle Shoals, AL United States
  Connect »

William Clark, Site 0038

Alaska Urological Institute dba Alaska Clinical Research Center
Anchorage, AK United States
  Connect »

Mikhail Shtivelband, Site 0046

Ironwood Cancer And Research Centers, Pc
Chandler, AZ United States
  Connect »

J Thaddeus Beck, Site 0028

Highlands Oncology Group, P.A.
Fayetteville, AR United States
  Connect »

Edward Mcclay, Site 0053

Encinitas, CA United States
  Connect »

Nishan Tchekmedyian, Site 0066

Pacific Shores Medical Group
Long Beach, CA United States
  Connect »

Lasika Seneviratne, Site 0019

Los Angeles Cancer Network
Los Angeles, CA United States
  Connect »

Alexandra Drakaki, Site 0030

UCLA Hematology Oncology
Los Angeles, CA United States
  Connect »

Hugo Hool, Site 0013

Torrance Health Association
Redondo Beach, CA United States
  Connect »

Helen Moon, Site 0068

Kaiser Permanente Medical Group - Southern California
Riverside, CA United States
  Connect »

Charles Redfern, Site 0035

Sharp Memorial Hospital
San Diego, CA United States
  Connect »

Brian Dicarlo, Site 0018

Coastal Integrative Cancer Care
San Luis Obispo, CA United States
  Connect »

Robert Dichmann, Site 0072

Central Coast Med Oncology
Santa Maria, CA United States
  Connect »

Ivor Percent, Site 0033

Florida Cancer Specialists S.
Fort Myers, FL United States
  Connect »

Rakesh Singal, Site 0031

University Of Miami/Sylvester Cancer Center
Miami, FL United States
  Connect »

Julio Hajdenberg, Site 0020

UF Health Cancer Center at Orlando Health
Orlando, FL United States
  Connect »

Lucio Gordan, Site 0032

Florida Cancer Specialists
Saint Petersburg, FL United States
  Connect »

Bradley Carthon, Site 0011

Emory University - Winship Cancer Institute
Atlanta, GA United States
  Connect »

Robert Galamaga, Site 0014

Illinois Cancer Specialists
Niles, IL United States
  Connect »

Sunil Babu, Site 0012

Ft. Wayne Med Onco-Hema Inc
Fort Wayne, IN United States
  Connect »

Shaker Dakhil, Site 0017

Cancer Center Of Kansas
Wichita, KS United States
  Connect »

Arash Rezazadeh Kalebasty, Site 0027

Norton Cancer Institute
Louisville, KY United States
  Connect »

Samith Kochuparambil, Site 0009

Minnesota Oncology Hematology
Minneapolis, MN United States
  Connect »

Gautam Jha, Site 0050

Southdale Cancer Clinic
Minneapolis, MN United States
  Connect »

Site 0075

Local Institution
Saint Louis Park, MN United States
  Connect »

John Hrom, Site 0045

Hattiesburg Clinic
Hattiesburg, MS United States
  Connect »

Justin Baker, Site 0070

Jackson Oncology Associates, Pllc
Jackson, MS United States
  Connect »

Peter Van Veldhuizen, Site 0034

HCA Midwest Division
Kansas City, MO United States
  Connect »

Mehmet Sitki Copur, Site 0021

St. Francis Cancer Treatment Center
Grand Island, NE United States
  Connect »

Oscar Goodman, Site 0005

Comprehensive Cancer Centers of Nevada
Las Vegas, NV United States
  Connect »

Robert Alter, Site 0023

John Theurer Cancer Center
Hackensack, NJ United States
  Connect »

Richard Lauer, Site 0061

University Of New Mexico
Albuquerque, NM United States
  Connect »

Kevin Becker, Site 0041

Maimonides Medical Center
Brooklyn, NY United States
  Connect »

Ronald Harris, Site 0004

Broome Oncology
Johnson City, NY United States
  Connect »

Ana Molina, Site 0043

Weill Cornell Medical College
New York, NY United States
  Connect »

Michael Harrison, Site 0039

Duke University Medical Center
Durham, NC United States
  Connect »

Samer Kasbari, Site 0048

Southeastern Medical Oncology Center
Goldsboro, NC United States
  Connect »

Mark Olsen, Site 0003

Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, OK United States
  Connect »

Site 0073

Local Institution
Hershey, PA United States
  Connect »

Brian Lingerfelt, Site 0022

Charleston Hematology Oncology Associates, Pa
Charleston, SC United States
  Connect »

Harry Drabkin, Site 0026

Hollings Cancer Center
Charleston, SC United States
  Connect »

Heidi McKean, Site 0036

Avera Cancer Institute
Sioux Falls, SD United States
  Connect »

Edward Arrowsmith, Site 0037

Tennessee Oncology, PLLC
Chattanooga, TN United States
  Connect »

Johanna Bendell, Site 0002

Tennessee Oncology PLLC
Nashville, TN United States
  Connect »

Jeffrey Yorio, Site 0015

Texas Oncology
Austin, TX United States
  Connect »

Thomas Hutson, Site 0006

Texas Oncology
Dallas, TX United States
  Connect »

Stephen Richey, Site 0007

Texas Oncology-Fort Worth 12th Ave
Fort Worth, TX United States
  Connect »

David Watkins, Site 0060

Texas Oncology-Midland Allison Cancer Center
Midland, TX United States
  Connect »

Sharon Wilks, Site 0008

Texas Oncology
San Antonio, TX United States
  Connect »

Jeanny Aragon-Ching, Site 0042

Inova Research Center
Fairfax, VA United States
  Connect »

Joshua McFarlane, Site 0001

Virginia Cancer Institute
Richmond, VA United States
  Connect »

Scott Tykodi, Site 0051

Seattle Cancer Care Alliance
Seattle, WA United States
  Connect »

Arvind Chaudhry, Site 0010

Medical Oncology Associates
Spokane, WA United States
  Connect »

Thomas Giever, Site 0016

Yakima Valley Memorial Hospital/North Star Lodge
Yakima, WA United States
  Connect »

Hamid Emamekhoo, Site 0049

University of Wisconsin Clinical Science Center
Madison, WI United States
  Connect »